There’s a lot of focus on starting tirzepatide or semaglutide, but almost no structured discussion about stopping. The common wisdom is just that the weight comes back and food noise returns, which isn’t a strategy, it’s a surrender. I’m not stopping yet, but I’m thinking about what a planned exit would look like, because the goal is to use a tool, not become dependent on it. The pharmacokinetics are the place to start.
Tirzepatide has a five-day half-life. Stopping cold turkey isn’t an abrupt stop; it’s a forced, uncontrolled taper over about four weeks as plasma levels wash out. The appetite suppression and GI motility effects will decay along that curve. My own tracking shows the appetite suppression trough starting around day 5 post-injection, so I’d expect that window of returning hunger to just get wider and wider until it’s constant.
A planned taper seems more logical. Not just stretching the interval between shots, which creates bigger peaks and troughs, but a gradual dose reduction. Maybe stepping down from 10mg to 7.5mg for a month, then 5mg, and so on, while holding the injection interval constant. The goal would be to find the minimum effective dose that keeps food noise managed while you transfer the work back to behavioral tools.
And that’s the part that needs tracking. The variables to watch during a taper aren’t just the number on the scale. That’s a lagging indicator. The real work is in the leading indicators: 1.
Appetite/Hunger cues: Rating hunger on a 1-10 scale, logged daily. The goal is to see the pattern as the dose changes. I’d want to see the hunger ratings charted against the injection dates to map the decay curve subjectively. The correlation view in the CareClinic.